

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sue MacLeman
Date of last notice	2 September 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Interests held by: Dalroar Pty Ltd (MacLeman Investment Trust)
Date of change	9 December 2019
No. of securities held prior to change	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 41,470 Ordinary Shares 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021
Class	Options
Number acquired	Direct – Nil Indirect: Dalroar Pty Ltd (MacLeman Investment Trust) 50,000 Options
Number disposed	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Dalroar Pty Ltd (MacLeman Investment Trust) 50,000 Options Nil; approved at the Annual General Meeting held on 22 November 2019
<b>No. of securities held after change</b>	Direct: Nil Indirect: Interests held by Dalroar Pty Ltd (MacLeman Investment Trust): 41,470 Ordinary Shares 200,732 Options exercisable at \$0.578 ea, expiring 23 February 2021 50,000 Options at \$0.4228 ea, expiring 8 December 2024
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Options – issued under the Oventus Executive Option Plan as approved at the Annual General Meeting held on 22 November 2019

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

## Part 3 – <sup>+</sup>Closed period

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

Were the interests in the securities or contracts detailed above traded during a <sup>+</sup> closed period where prior written clearance was required?	Not in a closed period
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

---

<sup>+</sup> See chapter 19 for defined terms.